RT @MeralElRamahiMD: âï¸Ustekinumab+MTX vs. UST+PBO in PsA? â¡ï¸Additional MTX has no positive impact on UST effic
Tweet Content
⭐️Ustekinumab+MTX vs. UST+PBO in PsA?
➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function.
*️⃣Thus, no evident to add or maintain ongoing MTX when starting UST
Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
Show on Archive Page
On
Display in Search Results
On
PDQ
Off